You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

bNAb

Showing 1 - 25 of 30
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Broadly HIV-1 Neutralizing Antibodies in HIV-infected Mbeya,

Active, not recruiting
  • HIV/AIDS
    • Mbeya, Tanzania
      NIMR-Mbeya Medical Research Center (MMRC)
    Aug 5, 2022

    Human Immunodeficiency Virus Trial in New York, Philadelphia (3BNC117-LS, 10-1074-LS, N803)

    Not yet recruiting
    • Human Immunodeficiency Virus
    • New York, New York
    • +2 more
    Jul 12, 2022

    Hiv Trial in Denmark, United Kingdom (Romidepsin, 3BNC117, Antiretrovirals)

    Active, not recruiting
    • Hiv
    • Aalborg, Denmark
    • +6 more
    Sep 3, 2021

    HIV-1-infection Trial in Botswana, Malawi, South Africa (3BNC117-LS-J, 10-1074-LS-J, Placebo for 3BNC117-LS-J)

    Not yet recruiting
    • HIV-1-infection
    • Molepolole, Botswana
    • +8 more
    Sep 8, 2023

    HIV, AIDS, Immunologic Deficiency Syndrome, Acquired Trial in Boston (Ad26.Mos4.HIV, MVA-BN-HIV, PGT121)

    Recruiting
    • HIV
    • +4 more
    • Ad26.Mos4.HIV
    • +4 more
    • Boston, Massachusetts
      Beth Israel Deaconess Medical Center
    Apr 18, 2022

    HIV-1 Trial in Bethesda, New York (3BNC117-LS, 10-1074-LS, Sterile Saline)

    Recruiting
    • HIV-1
    • 3BNC117-LS
    • +2 more
    • Bethesda, Maryland
    • +1 more
    Jan 31, 2023

    Vaginal Microecology and Cervical Local Immune Function in

    Not yet recruiting
    • Uterine Fibroids
    • Microscopic examination of vaginal discharge
    • (no location specified)
    Sep 23, 2023

    Acute HIV Infection Trial in Brazil, Peru, United States (biological, other, drug)

    Not yet recruiting
    • Acute HIV Infection
    • VRC07-523LS
    • +3 more
    • Birmingham, Alabama
    • +35 more
    Jan 30, 2023

    HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)

    Not yet recruiting
    • HIV-1-infection
    • Mbeya, Tanzania
      National Institute for Medical Research-Mbeya Medical Resarch Ce
    Jun 6, 2023

    HIV/AIDS Trial in San Francisco (Combination Intervention)

    Active, not recruiting
    • HIV/AIDS
    • Combination Intervention
    • San Francisco, California
      Zuckerberg San Francisco General Hospital, University of Califor
    Mar 21, 2022

    HIV-1-infection Trial in London (ConM SOSIP, EDC ConM SOSIP, ConS UFO)

    Active, not recruiting
    • HIV-1-infection
    • ConM SOSIP
    • +4 more
    • London, United Kingdom
      NIHR Imperial Clinical Resarch Facility
    Jul 25, 2022

    HIV-1-infection Trial in United States (426c.Mod.Core-C4b 30 mcg, 426c.Mod.Core-C4b 100 mcg, 426c.Mod.Core-C4b 300 mcg)

    Recruiting
    • HIV-1-infection
    • 426c.Mod.Core-C4b 30 mcg
    • +3 more
    • Birmingham, Alabama
    • +5 more
    Jul 25, 2022

    Virus Diseases Trial in London (ConM SOSIP 50 ug and ConS UFO 50 ug, Mos3.1 100 ug, Mos3.2 100 ug)

    Active, not recruiting
    • Virus Diseases
    • ConM SOSIP 50 ug and ConS UFO 50 ug
    • +4 more
    • London, Please Select..., United Kingdom
      NIHR Imperial Clinical Research Facility
    Jul 25, 2022

    HIV-1-infection Trial in Pathum Wan (VRC07-523LS, PGDM1400LS, N-803)

    Not yet recruiting
    • HIV-1-infection
    • VRC07-523LS
    • +7 more
    • Pathum Wan, Bangkok, Thailand
    • +1 more
    Mar 8, 2023

    During Pregnancy and Mechanism of Breast Iodine Homeostasis

    Not yet recruiting
    • Nutritional Requirements
    • dietary intervention
    • Lanzhou, China
    • +1 more
    Feb 15, 2023

    HIV, Systemic Lupus Erythematosus Trial in Durham (AIDSVAX® B/E)

    Completed
    Has Results
    • HIV Infections
    • Systemic Lupus Erythematosus
    • AIDSVAX® B/E
    • Durham, North Carolina
      Duke Human Vaccine Institute CRS
    Jan 31, 2022

    HIV Trial run by the National Institute of Allergy and Infectious Diseases (NIAID) (VRC-HIVMAB0115-00-AB)

    Recruiting
    • HIV
    • VRC-HIVMAB0115-00-AB
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    HIV, HIV/AIDS, HIV-1 Infection Trial in Philadelphia (Pegylated Interferon alpha 2b (peg-IFN-a2b), 3BNC117 + 10-1074)

    Unknown status
    • HIV
    • +2 more
    • Pegylated Interferon alpha 2b (peg-IFN-α2b)
    • 3BNC117 + 10-1074
    • Philadelphia, Pennsylvania
    • +1 more
    Jun 22, 2021

    Time Restricted Feeding, Overweight and Obesity, Inflammation Trial in Izola (Effects of calorie restriction and time-restricted

    Recruiting
    • Time Restricted Feeding
    • +8 more
    • Effects of calorie restriction and time-restricted eating on human health
    • Izola, Slovenia
      University of Primorska, Faculty of Health Sciences
    Feb 6, 2023

    HIV Trial in United States (N332-GT5 gp140 (IM, Bolus), N332-GT5 gp140 (IM, Fractioned), N332-GT5 gp140 (SC, Bolus))

    Not yet recruiting
    • HIV
    • N332-GT5 gp140 (IM, Bolus)
    • +7 more
    • San Francisco, California
    • +7 more
    Sep 8, 2023

    HIV Trial run by the NIAID (VRC-HIVMAB060-00-AB (VRC01), 10-1074, Normal Saline Placebo)

    Terminated
    Has Results
    • HIV
    • VRC-HIVMAB060-00-AB (VRC01)
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Sep 22, 2021

    HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)

    Completed
    • HIV Antibodies
    • VRC-HIVMAB091-00-AB
    • EDP
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Oct 8, 2022

    HIV Trial in Columbus, Pittsburgh (Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine

    Recruiting
    • HIV Infections
    • Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant
    • +3 more
    • Columbus, Ohio
    • +1 more
    Apr 10, 2022

    HIV Infection Trial in United States (N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074)

    Recruiting
    • HIV Infection
    • N-803 (IL-15 Superagonist)
    • +2 more
    • Los Angeles, California
    • +11 more
    Sep 22, 2022

    HIV Trial run by the NIAID (3BNC117 and 10-1074, Placebo)

    Terminated
    Has Results
    • HIV
    • 3BNC117 and 10-1074
    • Placebo
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 18, 2022